Phase III Clinical Trials CROs in China

Nanjing-based clinical CRO and Pharmaron subsidiary providing one-stop clinical development services in China including regulatory affairs, clinical operations, pharmacovigilance, and bioanalysis.

China-based global CRO providing full clinical development services from Phase I through IV with strong site networks across China, Korea, and Southeast Asia.

Chinese CRO-turned-biotech providing clinical development services with deep oncology expertise, operating a portfolio of discovery through Phase III programs in solid tumors and hematological malignancies.

Shanghai-based specialised clinical CRO providing full clinical development services in China and APAC with expertise in navigating NMPA regulatory pathways for multinational pharmaceutical companies.

Chinese pharmaceutical company providing contract research and clinical development services for pharmaceutical companies seeking NMPA approvals in China.

Greater China operations of Australian CRO Novotech, providing full-service clinical trial management across mainland China, Hong Kong and Taiwan with NMPA submission expertise.

PPD's Chinese clinical operations providing Phase I-IV clinical development, regulatory strategy, and site management for multinational and domestic pharmaceutical companies in Greater China.

China's largest independent CRO providing comprehensive clinical development services from preclinical through post-marketing with operations across China, Asia, and globally.

Clinical division of WuXi AppTec providing end-to-end Phase I-IV clinical trial services across China and Asia with expertise in NMPA, FDA and EMA regulatory submissions.